Long-term Safety and Performance of the ARGOS-SC Suprachoroidal Pressure Sensor System in Patients With Glaucoma Underwent Non-penetrating Glaucoma Surgery
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Implandata Ophthalmic Products GmbH
With
CRO Dr. med Kottmann GmbH & Co. KG
This study is designed as a prospective, open-label, multicenter, single-arm clinical investigation. This study is a follow-up study to the ARGOS-SC01 study (NCT03756662). Patients who have graduated the ARGOS-SC01 study after 12 month follow-up will be asked to enroll in this study for an additional 24 month follow-up (month 12-36 post implantation). This study will be solely observational, as only patients who had implanted the device within the earlier study will be invited to join this ARGOS-SC01\_FU study.
The sensor was always implanted in one eye only which will be the study eye.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
\- Subjects of the ARGOS-SC01 study with an implanted ARGOS-SC suprachoroidal pressure sensor.